Management of anticoagulation during dermatosurgical procedures in Germany - results from a cross-sectional study.
BACKGROUND
Treatment with antiplatelet drugs (APD) and vitamin K antagonists (VKA) can be a challenge during the management of dermatosurgical interventions.


METHODS
We performed a cross-sectional study on the perioperative management of APD and VKA in dermatological private practices and clinics in Germany, using anonymized, standardized questionnaires.


RESULTS
233 responses were evaluated (response rate 37 %). Skin biopsies are performed in 82.7 % of offices and in 90.8 % of clinics despite treatment with VKA. Small excisions are done in 62.5 % of offices and 76.9 % of clinics during treatment with VKA, for large excision this applies to 11.9 % of offices and 33.8 % of clinics. Low-dose treatment with APD (#100 mg) does not hinder 80.4 % of private practices and 89.2 % of clinics to perform small excisions as well as 36.3 % and 53.8 %, respectively, to perform large excisions. Of private practitioners 67.3 % and 83.1 % of clinic-based dermato-surgeons do not consider high-dose APD a contraindication for small excisions, and 25.0 % and 41.5 %, respectively, for large excisions. Most frequently switching to heparin is performed 6-8 days prior to surgery and switching back 0-2 days after surgery.


CONCLUSIONS
Large differences in the perioperative management of anticoagulant therapy during dermatosurgical procedures have been identified. Further studies and guidelines should be developed.
Division of Evidence-Based Medicine, Department of Dermatology, Venereology and Allergology, Charité- University Medicine Berlin, Germany. alexander.nast@charite.de
Alexander
A
Nast
Henriette
H
Ernst
Stefanie
S
Rosumeck
Ricardo
R
Erdmann
Birte
B
Sporbeck
Joachim W
JW
Fluhr
D000925:Anticoagulants / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D062109:Dermatologic Surgical Procedures / Q000706:statistics & numerical data*; D005858:Germany / Q000453:epidemiology; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019106:Postoperative Hemorrhage / Q000453:epidemiology* / Q000517:prevention & control*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D015995:Prevalence; D018570:Risk Assessment; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014812:Vitamin K